Amgen ponies up $240M for Michigan discovery outfit's dendritic cell-based molecules for autoimmune disorders

In the massive immunology market, some of pharma’s biggest players are looking for novel pathways to treat disease areas already packed with big-name drugs. Now, with an immunology blockbuster of its own in Otezla, Amgen is ponying up to partner with a Michigan discovery outfit looking to use dendritic cells to churn up immune tolerance.